The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Citation: Neurodegenerative Disease Management. 8(2):73-80, 2018 04.PMID: 29564954Institution: MedStar Washington Hospital CenterDepartment: NeurologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Amantadine/tu [Therapeutic Use] | *Analgesics, Non-Narcotic/tu [Therapeutic Use] | *Dyskinesia, Drug-Induced/dt [Drug Therapy] | Antiparkinson Agents/ae [Adverse Effects] | Drug Delivery Systems | Humans | Levodopa/ae [Adverse Effects] | Parkinson Disease/dt [Drug Therapy]Year: 2018ISSN:- 1758-2024
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 29564954 | Available | 29564954 |
Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.
English